Professor Wang Zhiren
E-mail：zhirenwang@scut.edu.cn
2024-Present South China University of Technology, Professor
2019-2024 The University of Arizona, College of Pharmacy, Postdoctoral Researcher
2017-2018 Sun Yat-Sen University, Associate Researcher
2016-2016 University of California San Diego, PostdoctoralScholar Researcher
2011-2016 Sun Yat-Sen University, School of Pharmaceutical Sciences, Ph.D
Nanomedicines, Drug delivery, Phospholipids, Liposomal drugs
The Dr. Wang’s Laboratory has maintained a sustained research focus on the rational design and development of engineered phospholipid-based nanovesicles as modular drug delivery platforms. These biomimetic systems exhibit significant potential to advance tumor immunotherapy through enhanced spatiotemporal control of immune modulation. Furthermore, their tunable physicochemical properties offer novel therapeutic paradigms for targeted intervention in neurodegenerative pathologies. Dr. Wang has authored over 20 peer-reviewed research articles in high-impact journals including Nature Nanotechnology, Nature Cancer, and Nature Communications, as well as leading specialty journals (Biomaterials, Journal of Controlled Release, Journal of Medicinal Chemistry). Additionally, Dr. Wang holds 4 granted patents in China and the United States.
1. Zhiren Wang, Wenpan Li, Yanhao Jiang, Teng Ma, Mengwen Li, etal. A sphingolipid-derived Paclitaxel nanovesicle enhancesefficacy of combination therapies in triple negative breast cancer andpancreatic cancer. Nature Cancer2025, 6,1734-1753.
2. Zhiren Wang, Jianqin Lu. A sphingolipid-derived paclitaxel nanovesicle for improvedcancer therapy. NatureCancer 2025, 6, 1619-1620.
3. Zhiren Wang,Nicholas Little, Jiawei Chen, Kevin Tyler Lambesis, Kimberly Thi Le, et al.Immunogenic camptothesome nanovesicles comprised by sphingomyelin-derived camptothecinbilayers for safe and synergistic cancer immunochemotherapy. Nature Nanotechnology 2021, 16, 1130-1140.
4. Zhiren Wang,Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Leyla Estrella Cordova, et al. Sphingomyelin-derivednanovesicles for the delivery of the IDO1 inhibitor epacadostat enhancemetastatic and post-surgical melanoma immunotherapy. Nature Communications, 2023, 14, 7235.
5. Zhiren Wang,Wenpan Li, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, et al.Cholesterol-modified sphingomyelin chimeric lipid bilayer for fortified therapeuticdelivery. Nature Communications, 2024,15, 2073.
6. Zhiren Wang,Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Jinha Chung, et al. Camptothesome-basedcombination nanotherapeutic regimen for improved colorectal cancerimmunochemotherapy. Biomaterials, 2024, 306, 122477.
7. Zhiren Wang,Wenpan Li, Jonghan Park, Karina Marie Gonzalez, Aaron James Scott, et al. Camptothesome elicits immunogenic cell death to boost colorectalcancer immune checkpoint blockade. Journal ofControlled Release, 2022, 349, 929-939.
8. Zhiren Wang, Jiawei Chen, NicholasLittle, Jianqin Lu. Self-assembling prodrug nanotherapeuticsfor synergistic tumor targeted drug delivery. Acta Biomaterialia 2020, 111,20-28.
9. Zhiren Wang, Karina Marie Gonzalez, LeylaEstrella Cordova, Jianqin Lu. Nanotechnology-empowered therapeutics targetingneurodegenerative diseases. WIREs Nanomedicine & Nanobiotechnology 2023, 15,e1907.
10. Zhiren Wang,Jinhui Hu, Xiaoping Yang, Xing Feng, Xingshu Li, et al. Design, synthesis, and evaluationof orally bioavailable quinoline–indole derivatives as innovative multitarget-directedligands: promotion of cell proliferation in the adult murine hippocampus forthe treatment of Alzheimer’s disease. Journal of Medicinal Chemistry 2018, 61,1871-1894.
11. Zhiren Wang,Yali Wang, Bo Wang, Wenrui Li, Ling Huang, et al. Design, synthesisand evaluation of orally available clioquinol-moracin M hybrids as multi-target-directedligands for cognitive improvement in a rat model of neurodegeneration inAlzheimer’s disease. Journal of Medicinal Chemistry 2015, 58, 8616-8637.